SAB Biotherapeutics (SABS) Expected to Post Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.29) per share and revenue of $0.1250 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, analysts expect SAB Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $3.48 on Thursday. The company has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $3.84. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $5.15. The firm has a market cap of $266.08 million, a price-to-earnings ratio of -1.65 and a beta of 0.52.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds have recently modified their holdings of SABS. Perceptive Advisors LLC bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at about $3,004,000. Millennium Management LLC bought a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $1,212,000. Balyasny Asset Management L.P. purchased a new position in SAB Biotherapeutics during the 4th quarter valued at about $1,778,000. ADAR1 Capital Management LLC increased its holdings in SAB Biotherapeutics by 75.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after purchasing an additional 11,344 shares during the period. Finally, ExodusPoint Capital Management LP purchased a new position in SAB Biotherapeutics during the 4th quarter valued at about $322,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on SABS shares. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw reaffirmed a “buy” rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.